tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Syros Pharmaceuticals (SYRS), Co-Diagnostics (CODX) and Iterum Therapeutics (ITRM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Syros Pharmaceuticals (SYRSResearch Report), Co-Diagnostics (CODXResearch Report) and Iterum Therapeutics (ITRMResearch Report).

Syros Pharmaceuticals (SYRS)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Syros Pharmaceuticals, with a price target of $6.00. The company’s shares closed last Monday at $0.86, close to its 52-week low of $0.65.

According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -15.8% and a 34.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics.

Currently, the analyst consensus on Syros Pharmaceuticals is a Strong Buy with an average price target of $9.60, which is a 1003.4% upside from current levels. In a report issued on July 5, Brookline Capital Markets also maintained a Buy rating on the stock with a $19.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Co-Diagnostics (CODX)

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Co-Diagnostics today and set a price target of $12.00. The company’s shares closed last Monday at $6.13.

According to TipRanks.com, Chen has 0 stars on 0-5 stars ranking scale with an average return of -9.3% and a 33.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

Currently, the analyst consensus on Co-Diagnostics is a Moderate Buy with an average price target of $12.00.

Iterum Therapeutics (ITRM)

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Iterum Therapeutics today. The company’s shares closed last Monday at $0.34, close to its 52-week low of $0.18.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 10.0% and a 40.3% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Aurinia Pharmaceuticals, and Paratek Pharmaceuticals.

Iterum Therapeutics has an analyst consensus of Hold.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SYRS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More